Affordable Access

Access to the full text

Outcomes after a 1-Year Treatment with Ranibizumab for Diabetic Macular Edema in a Clinical Setting

Authors
  • Hrarat, Linda
  • Fajnkuchen, Franck
  • Boubaya, Marouane
  • Lévy, Vincent
  • Sarda, Valérie
  • Grenet, Typhaine
  • Nghiem-Buffet, Sylvia
  • Chaine, Gilles
  • Giocanti-Auregan, Audrey
Type
Published Article
Journal
Ophthalmologica
Publisher
S. Karger AG
Publication Date
Nov 30, 2016
Volume
236
Issue
4
Pages
207–214
Identifiers
DOI: 10.1159/000453006
PMID: 27898414
Source
Karger
Keywords
License
Green
External links

Abstract

Purpose: The aim of this study was to assess the efficacy and safety of ranibizumab in patients with diabetic macular edema (DME). Methods: We conducted a retrospective analysis of consecutive patients with vision loss due to DME who were treated with ranibizumab. All patients received a loading dose of 3 monthly injections followed by re-treatments on an as-needed basis. The primary endpoint was the change in best-corrected visual acuity (BCVA) at 12 months. Secondary endpoints were the change in central retinal thickness (CRT) and the number of intravitreal injections (IVI) at 12 months. Results: One hundred and six eyes of 78 patients were included. BCVA changed from 48.3 (20/100) letters at baseline to 59.0 letters (20/63) at 12 months (p < 0.0001; mean gain: +10.7 letters), and 38% of the patients had a final BCVA >70 letters. CRT decreased from 519 µm at baseline to 355 µm at 12 months (p < 0.0001). The threshold of the first quartile of the baseline VA was 40 letters. Patients with a baseline VA >40 letters had a higher final VA of 66 ± 14 letters (20/50) versus 43 ± 18 letters (20/125) for patients with a baseline VA ≤40 letters (p < 0.0001). A mean number of 5.4 (3-10) IVI were administered. Conclusion: This study conducted in a clinical setting confirms the results of previous randomized trials. The final BCVA was mainly influenced by the baseline BCVA, which supports the utility of early DME treatment before patients experience a severe vision loss.

Report this publication

Statistics

Seen <100 times